CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
PED-CITN-03 Pediatric CITN Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma Pediatric CIRB
PEPN1812 PEP-CTN A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia Pediatric CIRB
PEPN1924 PEP-CTN A Phase 2 Study of DS-8201A (NSC# 807708, IND# TBD) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma Pediatric CIRB
PEPN2011 PEP-CTN A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Pediatric CIRB
PEPN2111 PEP-CTN A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# TBD) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma Pediatric CIRB
PEPN2112 COG A Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors Pediatric CIRB
PEPN2113 COG A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy Pediatric CIRB
PEPN2121 PEP-CTN A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Pediatric CIRB
PEPN21EHR/PBTC-N15 Pediatric CITN Pilot Study to Enable Electronic Laboratory Data Transfer into Medidata Rave Pediatric CIRB
PEPN22P1 COG A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables Pediatric CIRB